Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Gross Margin: 2011-2025

Historic Gross Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Sep 2025 value amounting to 42.96%.

  • Iovance Biotherapeutics' Gross Margin fell 321.00% to 42.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.78%, marking a year-over-year decrease of 321.00%. This contributed to the annual value of 24.43% for FY2024, which is 82897.00% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Gross Margin is 42.96%, which was up 683.30% from 5.48% recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Gross Margin ranged from a high of 100.00% in Q2 2023 and a low of -915.52% during Q1 2024.
  • Moreover, its 3-year median value for Gross Margin was 2.32% (2024), whereas its average is -234.66%.
  • In the last 5 years, Iovance Biotherapeutics' Gross Margin plummeted by 10,084bps in 2024 and then spiked by 91,468bps in 2025.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Gross Margin stood at -805.60% in 2023, then surged by 81,260bps to 7.00% in 2024, then crashed by 321bps to 42.96% in 2025.
  • Its Gross Margin was 42.96% in Q3 2025, compared to 5.48% in Q2 2025 and -0.85% in Q1 2025.